EPP Events bring unexceptional networking and conversations with
Thought Leaders, Pricing and Revenue Growth Management experts.
If you have any questions about the event or if you would like to be part of our 2023 edition, please Contact Sabrina Wilson at firstname.lastname@example.org
Our preliminary speaker faculty includes:
Neil Palmer is the former CEO of PDCI Market Access Inc. (PDCI), Canada’s leading pricing and reimbursement consultancy he co-founded in 1996. PDCI became a business unit of McKesson Canada in December 2020 where Neil continues to serves as Senior Strategic Adviser. Prior to PDCI, Neil worked with the Patented Medicine Prices Review Board (PMPRB) where his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to the PMPRB, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilization. After completing his studies at the University of Western Ontario, Neil began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care. Neil was previously an Adjunct Assistant Professor at the University of Southern California School of Pharmacy graduate program in Health Care Decision Analysis where he lectured on health technology assessment, pricing and market access from a global perspective. He has presented extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe.
Slate Mountains Capital
Sebastian Gensior is an entrepreneurial-minded professional, with over a decade of experience in the life science, healthcare, and pharmaceutical sector. With a significant focus on market access and policy strategies, he regularly conducts comprehensive evaluations of early and late-stage pharmaceutical assets and advises investors and healthcare companies. Sebastian's career highlights include pivotal roles at Abbott, Roche, and Edelman, where he made significant contributions to market access policy, global health training programs, and public relations strategies, respectively.
Director, EU Pricing & Reimbursement Lead
Global Head, Value, Access & Pricing
Capability Lead Pricing, Contracting and Tendering
Michael Hemmann serves as the Capability Lead for Pricing, Contracting, and Tendering within the Global Healthcare Affairs & Market Access team at Boehringer Ingelheim. In this capacity, he plays a pivotal role in enhancing market access capabilities for his colleagues across various markets and therapeutic areas. Michael's current focus is on devising innovative pricing and contracting solutions that aim to expand the reach of Boehringer Ingelheim's products to a broader patient population. Before joining Boehringer Ingelheim, Michael spent over 15 years at Novo Nordisk, where he held various positions in Market Access, Pricing, Market Research, and Analytics. His extensive background in the pharmaceutical industry has equipped him with valuable insights and expertise, making him a key contributor to improve access for the medications of his company.
Former Advisor to NICE, Lecturer
University of Portsmouth
Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network. Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, is an Editorial Content Adviser to Guidelines, and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology. Omar has served a position on the External Reference Group on Cost Impact Modelling for NICE for 6 years and was subsequently appointed Panel Member for the newly formed Adoption & Impact Program Reference for NICE. He advises foreign investors (US Embassy) on ‘Value Based Assessments (hosted by the UK Department of Trade & Industry) and recently delivered a Healthcare NHS Reform program to over 40 Healthcare Insurance Provider delegates visiting from the US. Last year he was invited to address the Italian Healthcare Senate [Senato della Repubblica] on Pharmaco-economic Evaluation & Sustainability Models of Healthcare and featured at the Westminster Health Forum Keynote Seminars [chaired by Lord Howe, All Party Parliamentary Group on Pharmacy] on the Future for Pharmacy Commissioning, Organisation & Delivery. At this current time he has embarked on a PhD with his doctorate thesis entitled “Value Based Pricing & Outcomes Based, Innovative Contracting of New Medicines”
Revenue Management Labs
Sr. Director, Global Market Access - Global Rx Pricing Head
Director Project Management
Principal Life Sciences
Partner - Strategy, M&A & Analytics leader – Lifesciences
Marc Abels is a Deloitte Consulting Partner, with 22 years of experience in sales & marketing and a deep expertise in pricing. He leads the Strategy & Analytics department (230 consultants) for Deloitte Belgium and is a recognised ‘Pricing’ expert within Deloitte globally.
His work mainly focuses in the life sciences industry (pharma, animal health and medical devices) and Marc’s expertise touches all aspect of commercial excellence in that area, from pricing & profitability management to product lifecycle optimization including loss of exclusivity strategy.
Head of Government Affairs and Patient Advocacy, EMEA & APAC
Thomas Bols is PTC Therapeutics’ Head of Government Affairs and Patient Engagement, EMEA & APAC.
Thomas joined PTC in March 2020, continuing his career in the biopharmaceutical industry, having held positions for Amgen, Merck, Biogen and, most recently, at the global association, DIA. He has worked in the interconnected areas of market access, government affairs, public affairs, health policy, corporate communications, and patient advocacy. In each role, Thomas has spearheaded initiatives that are crucial to bringing much-needed medicines to patients. Throughout his career, Thomas has advised and represented companies, as well as industry federations in engagements with policy makers, patient representatives, media, regulators, payers, and other national and European health policy platforms.
Thomas is a board member of Europabio since June 2022. In the past he held other board positions at several European associations, such as Europabio and EUCOPE, chaired a variety of working groups related to regulatory and access issues within EFPIA, and has been a member of the European Commission High Level Pharmaceutical Forum (2005-2008) and its Process on Corporate Responsibility in the Field of Pharmaceuticals (2010-2012).
Industry Principal for Life and Sciences
Alejandra (Sandra) Garitonandía is the Life Sciences Industry Principal for Life Sciences at Vistex EMEA. She is a Life Sciences passionate and specialized in Pricing and Revenue Management for Life Sciences with background in medical and business educational studies. She has a background in medical and business educational studies but also a broad experience as an IT professional. Her Specialization area is where business processes meet the IT systems and how to support efficient end-to-end revenue management.
Goedele van Haasteren
Swiss Ministry of Health
Bundesamt für Gesundheit
Kaushal is a pricing transformation consultant currently engaged in Merck and based out of Germany. With around 17 plus years of experience in commercial and pricing, Kaushal has been able to drive pricing transformation initiatives in Pharma, Life Sciences and Manufacturing companies. Kaushal has successfully set-up industry standard contracting and pricing ‘CoE’ functions. As a subject matter expert in pricing, he has authored though leadership papers and is a professional coach and trainer on the topic. Kaushal has an MBA degree in marketing and has worked internationally in US, UK, Japan, Europe and India.
Global Healthcare Executive
Giovanny is a seasoned pharmaceutical executive with extensive experience in management roles across LatAm and Novartis Global HQ. Passionate about improving patient access to medicines, he focuses on two key areas:
Market Shaping and Strategy: Giovanny fosters access and pricing strategy adaptation, ensuring successful commercialization and reimbursement of innovative products. He collaborates with healthcare stakeholders to understand their priorities and co-create common goals, driving innovation adoption.
Patient-Centric Pricing: Through research-based practices, Giovanny investigates how final prices impact healthcare affordability and patient journeys. He works to minimize the negative influence of pharmaceutical mark-ups and VAT on patient access to medicines.
Giovanny holds an MBA and a Master's in Marketing and Commercial Management from Universidad Complutense, Madrid. He has completed Management & Leadership programs in diverse universities and business schools, including Cambridge, London Business School, Columbia University, IESA, Universidad de Los Andes, ITAM, ESPM, and IAE.
Head of Global Pricing Excellence
Senior Director Professional Services
General Manager Global Pricing Access Solution
Faculty of Medicine of the University of Geneva, Institute of Global Health
Partner, Global Pharma
Andrea Mantovani is a Partner at Alira Health, leading access, public affairs, patient engagement, digital, and commercial excellence strategies for the Global Pharma Practice.
Andrea joined Alira Health in 2021, with more than 27 years of consulting and pharmaceutical industry experience. His expertise is in strategy, marketing and sales, public affairs, pricing, and market access, with a track record of over 30 transactions. Andrea’s work focuses on international projects across the United States, EU, Africa, Latin America, and Asia Pacific markets at the global, regional, and affiliate levels across therapeutic areas including oncology, hematology, cardiometabolic, immunology, and rare disease.
Prior to joining Alira Health, Andrea worked at Andersen Consulting (now Accenture) and held senior management roles for big pharma companies in the UK, Spain, and Italy, including Sanofi, Amgen, Abbott, and Novartis, where he spent five years at the international headquarters, overseeing activities in 28 countries and spearheading transformational Value, Access & Pricing projects.
Andrea holds a degree in marketing and economics from the University of Verona, and an MBA from SDA Bocconi Business School, including courses in healthcare and pharmaceuticals. He has received additional training in economics, pharmacoeconomics, and digital transformation.
He is a contract professor for Market Access and Public Affairs at LUISS Business School and an external lecturer for the MAMIL Master, a joint program by H-Farm and Humanitas University.
Global Pricing Analytic Innovation and North America
Strategy Principal Director - Pricing and Commercial Excellence Europe
Daniel Linder is Strategy Principal Director in Accenture’s European Pricing & Commercial strategy team. Since 2012, he has led more than 100 consulting projects for market-leading and mid-sized clients from across B2B and B2C industries. His focus areas are among others pricing strategy, digital asset pricing and pricing software. He has won several consulting awards for his pricing approaches.